source
- Vertex posts strong Q2 earnings, but upcoming Sionna cystic fibrosis data casts a shadowVertex reported Q2 revenue from its cystic fibrosis portfolio exceeding $3.2 billion, beating estimates and prompting an upward revision of full‑year revenue guidance to $13.1‑$13.2 billion. Analy…
- Vertex and AbCellera team up to develop next-generation T-cell engagers for autoimmune diseasesVertex Pharmaceuticals has entered a partnership with AbCellera to create next-generation T-cell engagers aimed at autoimmune diseases. AbCellera will receive an upfront payment of $28 million, wit…